The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing might have the potential to supply peace of thoughts to survivors of breast most cancers, as a survivor and...
The U.S. business launch of LYMPHIR (denileukin diftitox-cxdl), a novel most cancers immunotherapy for adults with relapsed or refractory stage 1 to...
